Phorum.AI
Phorum.AI revolutionizes biomanufacturing by leveraging cutting-edge AI models to optimize therapeutics production. They aim to reduce costs, waste, and time, thereby improving the accessibility of critical therapeutics. Their solutions address inefficiencies across the drug development lifecycle, from early candidate stages to QA/QC, enhancing effectiveness and reducing lead times. Phorum.AI's technology, including their proprietary PHORUM-GPT model, predicts synthesis risks, recommends purification strategies, and improves formulation and production processes across various modalities like small molecules, peptides, mRNA, and cell & gene therapies. The company was founded in 2023 by Brad Pentelute and David Shrier, who recognized the opportunity to accelerate drug development through AI and computational chemistry. They have secured their first large-scale customer within five months of incorporation.
Phorum.AI
Phorum.AI revolutionizes biomanufacturing by leveraging cutting-edge AI models to optimize therapeutics production. They aim to reduce costs, waste, and time, thereby improving the accessibility of critical therapeutics. Their solutions address inefficiencies across the drug development lifecycle, from early candidate stages to QA/QC, enhancing effectiveness and reducing lead times. Phorum.AI's technology, including their proprietary PHORUM-GPT model, predicts synthesis risks, recommends purification strategies, and improves formulation and production processes across various modalities like small molecules, peptides, mRNA, and cell & gene therapies. The company was founded in 2023 by Brad Pentelute and David Shrier, who recognized the opportunity to accelerate drug development through AI and computational chemistry. They have secured their first large-scale customer within five months of incorporation.